Europska Unija - hrvatski - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilat - karcinom, stanice bubrega - antineoplastična sredstva - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastična sredstva - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilat - neoplazme štitnjače - antineoplastična sredstva - lenvima prikazan kao monoterapija za liječenje odraslih bolesnika s прогрессирующим, lokalno-uobičajena ili metastaze, diferencira (папиллярный/фолликулярный/hürthle staničnog) rak štitnjače (dtc), рефрактерным na konstanta Йоду (rai). lenvima prikazan kao monoterapija za liječenje odraslih bolesnika s preliminarnim ili operirati гепатоцеллюлярной karcinom (hcc), koji su primili ne prije sistemske terapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 30 mg/1 ml - 1 bočica sa 1 ml otopine za injekciju sadrži: 30 mg emicizumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 60 mg/0.4 ml - 1 bočica sa 0,4 ml otopine za injekciju sadrži: 60 mg emicizumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 105 mg/0.7 ml - 1 bočica sa 0,7 ml otopine za injekciju sadrži: 105 mg emicizumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 150 mg/1 ml - 1 bočica sa 1 ml otopine za injekciju sadrži: 150 mg emicizumaba

Europska Unija - hrvatski - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).